Adrenal Suppression With Mometasone Furoate/Formoterol

case reports and observational studies provide the impetus and rationale for future study in this area. Further encouraging evidence comes from a recent randomized, placebo-controlled trial of 210 patients with acute coronary syndromes or treated with a coronary stent on a thienopyridine, awaiting coronary artery bypass grafting. In this study, patients received IV cangrelor, a short-acting, reversible P2Y 12 -receptor inhibitor, or placebo for at least 48 h, which was stopped 1 to 6 h before surgery. Patients in the cangrelor group had lower levels of platelet reactivity with no signifi cant increase in coronary artery bypass grafting-related bleeding. 5 Whether this agent can be used safely in the noncardiac surgery setting has yet to be determined. The current evidence points toward a lack of consensus regarding best practices for patients with coronary stents undergoing noncardiac surgery. This is particularly true for bridging strategies, where the majority of guidelines provide no recommendations. Well-designed prospective observational and randomized trial evidence is needed to help defi ne future management strategies.